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Abstract
Chronic inflammatory events appear to play a fundamental role in Alzheimer’s disease (AD)-related neuropathological
changes, and to result in neuronal dysfunction and death. The inflammatory responses observed in the AD brain include
activation and proliferation of glial cells, together with up-regulation of inflammatory mediators and of free radicals. Along
with glial cells, neurons themselves can also react and contribute to neuroinflammatory changes in the AD brain, by serving
as sources of inflammatory mediators. Because excess cholesterol cannot be degraded in the brain, it must be excreted from
that organ as cholesterol oxidation products (oxysterols), in order to prevent its accumulation. Among risk factors for this
neurodegenerative disease, a mechanistic link between altered cholesterol metabolism and AD has been suggested;
oxysterols appear to be the missing linkers between the two, because of their neurotoxic effects. This study shows that 24-
hydroxycholesterol, 27-hydroxycholesterol, and 7b-hydroxycholesterol, the three oxysterols potentially implicated in AD
pathogenesis, induce some pro-inflammatory mediator expression in human neuroblastoma SH-SY5Y cells, via Toll-like
receptor-4/cyclooxygenase-2/membrane bound prostaglandin E synthase (TLR4/COX-2/mPGES-1); this clearly indicates that
oxysterols may promote neuroinflammatory changes in AD. To confirm this evidence, cells were incubated with the anti-
inflammatory flavonoid quercetin; remarkably, its anti-inflammatory effects in SH-SY5Y cells were enhanced when it was
loaded into b-cyclodextrin-dodecylcarbonate nanoparticles, versus cells pretreated with free quercetin. The goal of loading
quercetin into nanoparticles was to improve its permeation across the blood-brain barrier into the brain, and its
bioavailability to reach target cells. The findings show that this drug delivery system might be a new therapeutic strategy for
preventing or reducing AD progression.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder, typified by the pathological accumulation of b-amyloid
(Ab) peptides and neurofibrillary tangles (NFT) within the brain. It
is the leading cause of dementia [1,2]. Although the pathophys-
iology of AD remains poorly understood, considerable evidence
indicates that multifactorial components participate in the
progression of the disease, including inflammation, oxidative
stress, altered cholesterol metabolism, glial cell activation, and
dysregulation of intercellular communication among brain cells
[3].
There is now mounting evidence to suggest that chronic
inflammation plays a fundamental role in the progression of
neuropathological changes in AD, resulting in neuronal dysfunc-
tion and death [4–8]. In this connection, there is also increasing
evidence that central nervous system (CNS) and systemic
inflammation cannot be viewed in isolation [9]. Even low grade
systemic inflammation might have important CNS consequences
in AD individuals, exacerbating behavioral symptoms and
accelerating disease progression, due to the increased production
of local pro-inflammatory cytokines and chemokines, as well as of
reactive oxygen species (ROS) and nitric oxide (NO) [10,11]. The
detrimental effects of peripheral pro-inflammatory mediators in
the AD brain chiefly occur because these agents enter the brain,
together with infiltrating leukocytes, thanks to the increased blood-
brain barrier (BBB) permeability as the disease progresses [12,13].
The importance of neuroinflammatory processes has emerged
from intensive study of the brain of AD patients. These have
evidenced the activation and proliferation of microglia and
astrocytes, together with enhanced release of neurotoxic cytokines,
chemokines, complement components, inflammatory enzymes and
acute phase proteins, as well as increased free radical-mediated
oxidative stress [14–18]. However, it remains unclear whether
inflammation is a cause or a consequence of AD. Clinical and
experimental studies support the involvement of inflammatory
changes already in the early stages of AD, even before the
appearance of Ab deposits. One of the main outcomes of microglia
activation is thus the initiation of an innate immune response,
dominated by the release of pro-inflammatory cytokines. Inciden-
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tal to this are also phagocytosis of amyloid fibrils and large Ab
aggregates, suggesting an initial neuroprotective defense mecha-
nism [19,20]. In later stages of the disease, however, overproduc-
tion of inflammatory cytokines makes the microglia phagocytically
inactive [21]. Along with glial cells, more recent evidence suggests
that even neurons themselves react and contribute to the chronic
neuroinflammatory changes in AD, by serving as source of
inflammatory mediators [6].
The brain, the organ with the highest cholesterol concentration,
cannot itself degrade cholesterol. Important mechanism whereby
the brain eliminates excess cholesterol, in order to prevent its
accumulation, is through the formation, and excretion into the
circulation, of oxysterols, a class of cholesterol oxidation products
which, unlike cholesterol, can easily cross the BBB [22,23]. The
major oxysterols involved in this excretion mechanism are 24-
hydroxycholesterol (24-OH), and 27-hydroxycholesterol (27-OH).
Of note, the marked accumulation of 27-OH in the AD brain is
also due to an increased influx of this oxysterol across the BBB,
because of hypercholesterolemia [24] or damaged BBB integrity
[13]. A further compound, 7b-hydroxycholesterol (7b-OH), may
also derive in the brain from oxidation of cholesterol, following the
interaction of cholesterol with Ab and amyloid precursor protein
(APP) [25].
Regarding risk factors for AD, a growing body of epidemiolog-
ical and molecular evidence suggests there may be a mechanistic
link between altered brain cholesterol metabolism and AD, in
which process oxysterols appear to be the missing linkers
[22,23,26–28]. This idea has been supported by research pointing
to the involvement of 24-OH and 27-OH in neurotoxicity, mainly
by interacting with Ab peptide [23].
Among therapeutic strategies that might successfully target
ongoing brain inflammation during AD progression, dietary
polyphenols, which can cross the BBB [29], have recently been
proposed to play a role [30–35]. Among dietary polyphenols, the
flavonoid quercetin is the most promising compound for AD
prevention and therapy. Together with its ability to scavenge toxic
free radicals such as ROS, this multipotent bioflavonoid can
potentially reduce inflammatory processes [36–38]. To improve
polyphenols’ entrance into the brain, and their bioavailability and
ability to reach the target tissue of interest for AD, new and
particular delivery forms have been developed. One such method
involves the use of nanoparticle carriers coupled to polyphenols
[39–42]. This procedure applied to quercetin, for both oral and
intravenous administration, has shown promising results [43,44].
Since several oxysterols have been shown to elicit strong pro-
inflammatory responses in a variety of cell types [45–50], we tested
the hypothesis that 24-OH, 27-OH and 7b-OH might also
promote inflammation in human neuroblastoma SH-SY5Y cells.
It was hoped thus to provide clear evidence that oxysterols
contribute to neuroinflammatory changes in AD. The findings
demonstrate that these three oxysterols induce the expression of
some inflammatory mediators in SH-SY5Y cells via Toll-like
receptor-4/cyclooxygenase-2/membrane bound prostaglandin E
synthase (TLR4/COX-2/mPGES-1). To highlight the inflamma-
tory action of these oxysterols, the cells were then incubated with
the bioflavonoid quercetin, which is known to possess strong anti-
inflammatory properties. With the hope of finding a new delivery
form for quercetin, to improve its bioavailability and consequently
its anti-inflammatory activity, it was decided first to investigate, in
an in vitro experimental study, this ability of quercetin’s, when
loaded into b-cyclodextrin (b-CD)-dodecylcarbonate nanoparti-
cles. The anti-inflammatory effect of quercetin carried by
nanoparticles was markedly enhanced versus that of free
quercetin. This drug delivery system appears to be a potential
new therapeutic approach, which might increase the neuropro-
tective effects of quercetin, improving both its permeation across
the BBB into the brain, and its bioavailability to reach target cells.
Materials and Methods
Preparation and characterization of quercetin-b-CD-
dodecylcarbonate inclusion complexes
The quercetin-b-CD-dodecylcarbonate inclusion complex was
obtained by adding a suitable amount of quercetin to a
dodecylcarbonate water/ethanol solution (75:25 v/v) at a concen-
tration of 10 mg/ml. This inclusion complex was prepared and
characterized as described elsewhere for the alkylcarbonates of c-
cyclodextrin [51]. b-CD was a kind gift from Roquette (Lestrem,
France). The amount of quercetin complexed was determined
spectrophotometrically at 370 nm after dilution of a weighed
amount of the complex in ethanol. After characterization, the
complexes were used to prepare the nanoparticles.
Preparation and characterization of coumarin 6-b-CD-
dodecylcarbonate inclusion complexes
An excess of coumarin 6 (4 mg), as fluorescent marker, was
added to b-CD dodecylcarbonate water/ethanol solution (75:25
v/v) (10 mg/ml) to prepare fluorescent inclusion complexes. The
suspension was left at room temperature in the dark for 5 days and
then centrifuged. The supernatant was separated and freeze-dried
to obtain the complex as powder form. The coumarin 6-b-CD-
dodecylcarbonate inclusion complex was characterized by Differ-
ential Scanning Calorimetry [51] and by fluorescent spectroscopy
(lex = 450 nm and lem = 490 nm) using a Shimadzu RF-551
instrument.
Preparation, characterization and in vitro release study of
quercetin-loaded b-CD-dodecylcarbonate nanoparticles
Quercetin-loaded nanoparticles were prepared using dodecyl-
carbonates pre-loaded as a complex. Nanoparticles were obtained
by the solvent injection technique as described elsewhere [52,53].
Briefly the b-CD-dodecylcarbonate (20 mg) was dissolved in
ethanol (3 ml); the solution was then added drop-wise to 20 ml
water under stirring, to form b-CD-dodecylcarbonate based
nanoparticles. After purification, nanoparticles were freeze-dried
to obtain nanoparticles in powder form. Fluorescent nanoparticles
were obtained with the same method using coumarin 6-b-CD-
dodecylcarbonate inclusion complexes.
The average diameter and polydispersity index of nanoparticles
were determined by Photon Correlation Spectroscopy, using a 90
PLUS instrument (Brookhaven, NY, USA) at a fixed angle of 90u
and a temperature of 25uC. The electrophoretic mobility and zeta
potential of nanoparticles were determined using a 90 Plus
instrument (Brookhaven). The electrophoretic mobility measured
was converted into zeta potential using the Smoluchowsky
equation [54]. The nanoparticles’ morphology was evaluated by
Transmission Electron Microscopy using a Philips CM10 instru-
ment (Eindoven, NL). The amount of quercetin incorporated into
the nanoparticles was determined spectrophotometrically at
370 nm after dilution of a weighed amount of the complex in
ethanol.
In vitro quercetin release experiments were carried out by the
dialysis bag technique. A weighed amount of freeze-dried
nanoparticles was dispersed in phosphate-buffered saline (PBS)
pH 7.4 (2 ml), and placed in the donor compartment for 24 h.
The receiving compartment was filled with a solution of 1%
Tween 80/PBS pH 7.4 (50 ml). Withdrawn solutions were then
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analyzed spectrophotometrically to determine the concentration of
quercetin.
Cell viability assay
To test the cytotoxic effects of the b-CD-dodecylcarbonate
nanoparticles alone or complexed with quercetin, cells were
incubated with the compounds or left untreated for 48 h. After
treatment, cell viability was measured in terms of the release of the
enzyme lactate dehydrogenase (LDH). LDH activity was deter-
mined in culture medium using a photometrical assay based on the
conversion of pyruvic acid to lactic acid by this enzyme, in the
presence of reduced NADH. Control and nanoparticle supple-
mented cell values are expressed as percentages of total LDH
released by untreated cells (100%), which were lysed with PBS plus
5% Triton X-100.
Analysis of cell uptake of fluorescent nanoparticles by
confocal laser microscopy
SH-SY5Y cells were grown on glass slides and, after treatments
with coumarin 6-b-CD-dodecylcarbonate nanoparticles for the
indicated times, specimens were washed (0.1 M PBS) and
mounted with glycerol/distilled water (1:1) plus 0.1% NaN3.
Slides were observed through the LSM510 confocal laser
microscope (Carl Zeiss SpA, Arese, Milan, Italy) equipped with
an inverted microscope with Plan-NEOFLUAR lenses (40X/
0.75).
Cell culture and treatments
Human neuroblastoma SH-SY5Y cells were grown in RPMI
1640 medium containing 10% fetal bovine serum, 2 mM
glutamine, 1% non-essential aminoacids and 1% antibiotic
mixture (penicillin-streptomycin-amphotericin). Cells were incu-
bated with 7b-OH, or 24-OH, or 27-OH (Steraloids, Newport,
RI, USA), all at the non-cytotoxic final concentration of 5 mM, or
with 15 mM oxysterol mixture (comprising 7b-OH, 24-OH, plus
27-OH, each present at the concentration of 5 mM), in all cases
dissolved in ethanol (solvent). Untreated cells were taken as
controls, and cells treated with 31.2 mM or 93.6 mM ethanol
(equivalent concentrations of ethanol corresponding to 5 mM or
15 mM oxysterol mixture, respectively) as solvent controls. Cells
Figure 1. Effect of oxysterols on expression of CD36, b1-integrin, IL-8, MCP-1, and MMP-9. Gene expression was quantified by real-time
RT-PCR in SH-SY5Y cells treated for 6 h with 5 mM 7b-hydroxycholesterol (7b-OH), 24-hydroxycholesterol (24-OH), 27-hydroxycholesterol (27-OH) or
with a 15 mM mixture of these three oxysterols. Untreated cells (Control) were taken as controls. Data, normalized to b2-microglobulin, are expressed
as mean values 6 SD of three different experiments. *P,0.05, **P,0.01, and ***P,0.001 vs. control.
doi:10.1371/journal.pone.0096795.g001
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supplemented with blank nanoparticles (not loaded with quercetin)
or with blank nanoparticles (1 h pretreatment) plus oxysterols,
were taken as internal controls. In experiments, some cells were
pretreated (1 h) with 5 mM free quercetin (QF) (Sigma-Aldrich,
Milan, Italy) or with 5 mM quercetin loaded into nanoparticles
(QN) before oxysterol treatment. Incubation times for all
experiments are reported in the Results section and Figure
legends.
RNA extraction and cDNA synthesis
Total RNA was extracted using TRIzol Reagent (Applied
Biosystems, Monza, Italy) following the manufacturer’s instruc-
tions. RNA was dissolved in RNase-free water fortified with
RNase inhibitors (RNase SUPERase-In; Ambion, Austin, TX,
USA). The amount and purity (A260/A280 ratio) of the extracted
RNA were assessed spectrophotometrically. cDNA was synthe-
sized by reverse transcription from 2 mg RNA with a commercial
kit (High-Capacity cDNA Reverse Transcription Kit; Applied
Biosystems) following the manufacturer’s instructions.
Real time RT-PCR
Singleplex real-time RT-PCR was performed on 30 ng of
cDNA using TaqMan Gene Expression Assay kits prepared for
human CD36, b1-integrin, interleukin 8 (IL-8), monocyte-
Figure 2. Cell viability and cell uptake of b-CD-dodecylcarbonate nanoparticles. A) SH-SY5Y cells were incubated with b-CD-
dodecylcarbonate nanoparticles with (QN) or without (NPs) being loaded with quercetin (5 mM). Some cells were treated with 5 mM quercetin alone
(QF). Untreated cells (Control) were taken as controls. Cell viability was measured in terms of release of the enzyme lactate dehydrogenase (LDH), as
described in the Materials and Methods section. Data represent the mean values 6 SD of three different experiments. B) SH-SY5Y cells were
incubated with fluorescent coumarin 6-b-CD-dodecylcarbonate nanoparticles for the times indicated and then analyzed by confocal laser scanning
microscopy (40X/0.75).
doi:10.1371/journal.pone.0096795.g002
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chemoattractant protein-1 (MCP-1), matrix metalloproteinase-9
(MMP-9), TLR4, mPGES-1, and b2-microglobulin, TaqMan Fast
Universal PCR Master Mix, and 7500 Fast Real-Time PCR
System (Applied Biosystems). Negative controls did not include
cDNA. The oligonucleotide sequences are not revealed by the
manufacturer because of proprietary interests. The cycling
parameters were as follows: 20 s at 95uC for AmpErase UNG
activation, 3 s at 95uC for AmpliTaq Gold DNA polymerase
activation, 40 cycles of 3 s at 95uC (melting), and 30 s at 60uC
(annealing/extension). The fractional cycle number (Ct) at which
fluorescence passes the threshold in the amplification plot of
fluorescence signal versus cycle number was determined for each
gene considered. The results were then normalized to the
expression of b2-microglobulin, as housekeeping gene. b2-micro-
globulin was used as reference gene in all experiments, since
preliminary observations had shown that expression of this
housekeeping gene is not affected by oxysterol treatment. Relative
quantification of target gene expression was achieved with a
mathematical method [55].
Western blotting
Whole-cell extracts were prepared in ice-cold lysing buffer (1 ml
PBS) was added with 10 ml Triton X-100, 10 ml SDS 10%, 5 ml
DTT 1 M, 6 ml PMSF 0.1%, 10 ml aprotinin). Total proteins
(50 mg) were separated by electrophoresis in 10% denaturing
SDS/polyacrylamide gel, then transferred to Hybond ECL
nitrocellulose membrane (GE Healthcare Europe, Milan, Italy).
After saturation of non-specific binding sites with 5% non-fat milk
in Tris-buffered saline (TBS) 1x-Tween 20 0.05%, the membrane
was immunoblotted overnight at 4uC with the primary antibody
against COX-2 (1:250) and subsequently probed with an anti-goat
secondary antibody (1:1000) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) overnight at 4uC. The membrane was
stripped (Restore Western Blot Stripping buffer, Pierce Biotech-
nology, Rockford, IL, USA) and re-immunoblotted with anti-actin
primary antibody (1:10000) and then with anti-rabbit secondary
antibodies (1:7500) (Santa Cruz Biotechnology Inc.). The immu-
noreactive bands were visualized through enhanced chemilumi-
nescence using the ECL-plus kit (GE Healthcare Europe) following
the manufacturer’s protocol. The bands were quantified by
densitometric analysis using Image J 1.43 software. The results
were evaluated as relative units determined by normalization of
the density of each band to that of the corresponding actin protein
band.
Statistical analysis
All values are expressed as means 6 SD. Data were analyzed
statistically using one-way ANOVA with Bonferroni’s post test for
multiple comparisons. Differences at P,0.05 were considered
statistically significant.
Results
24-OH, 27-OH, and 7b-OH promote pro-inflammatory
molecule expression in SH-SY5Y cells
The three oxysterols that have been linked to the pathophys-
iology of AD, 24-OH, 27-OH, and 7b-OH, were first checked for
their potential roles in modulating pro-inflammatory mediators in
human neuroblastoma SH-SY5Y cells. In these cells, a marked
and statistically-significant expression in various pro-inflammatory
molecules was observed after 6 h cell incubation with any of the
three oxysterols (5 mM) compared with untreated cells (controls).
As Figure 1 shows, there were net increases of mRNA levels in
chemokines IL-8 and MCP-1, the adhesion molecule b1-integrin,
the scavenger receptor CD36, and MMP-9. Particularly, and in
support of other reported findings, 24-OH and 27-OH appeared
to be effective at promoting inflammatory response in neurons.
The results were similar when cells were incubated with a mixture
of the three oxysterols (15 mM) for 6 h: also in this case, expression
of the inflammatory mediators considered was markedly increased
in cells incubated with the oxysterol mixture, compared with
controls, except for MMP-9 that was not significantly up-regulated
(Figure 1). Cells treated with ethanol (solvent) remained unaffected
(data not shown).
Quercetin-loaded nanoparticles prevent the expression
increase of inflammatory mediators induced by
oxysterols in SH-SY5Y cells.
The flavonoid quercetin, because of its anti-inflammatory
effects, might be a promising candidate for preventing neuroin-
flammation in the brain. With the hope of finding a new delivery
form for quercetin, to improve its permeation across the BBB into
the brain and enhance its bioavailability, and thus also its
therapeutic efficacy in AD, b-CD-dodecylcarbonate nanoparticles
containing quercetin were formulated [see Materials and Meth-
ods]. To support the hypothesis that better brain delivery and
bioavailability of quercetin would enhance its neuroprotective
activity by preventing or reducing inflammatory changes in the
brain, in our in vitro experimental model human neuroblastoma
SH-SY5Y cells were preincubated either with 5 mM free quercetin
(QF) or with 5 mM quercetin loaded into b-CD-dodecylcarbonate
nanoparticles (QN).
Before performing our cellular experiments, we tested whether
this type of nanoparticle, with or without being loaded with
quercetin, is cytotoxic and whether blank nanoparticles (not
loaded with quercetin) can be taken up by SH-SY5Y cells. The
nanoparticles were found to be non-cytotoxic. Cell viability was
measured in terms of release of LDH: neither blank nanoparticles
(NPs) nor quercetin-loaded nanoparticles (QN) had any effect on
viability of SH-SY5Y cells (Figure 2A). The cytotoxic effect of free
quercetin was also tested (QF) and no difference was observed
compared with control cells. Fluorescent b-CD-dodecylcarbonate
nanoparticles were taken up by the cells in a time-dependent-
manner, to a detectable extent already after 5 min of cell
Table 1. Average diameter, polydispersity index and zeta potential of the nanoparticle formulations.
Nanoparticle types Average diameter (nm) Polydispersity index Zeta potential (mV)
blank 19768.5 0.0860.02 230.262.4
quercetin-loaded 214.865.6 0.0860.02 226.561.5
b-coumarin-loaded 210.566.2 0.0960.02 225.761.2
doi:10.1371/journal.pone.0096795.t001
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incubation, with a maximum after 1 h (Figure 2B). They appear to
accumulate in a perinuclear compartment. This would indicate
that this carrier system might be useful for drug delivery into
neuronal cells. No intracellular fluorescence was detected in
control cells that had not been exposed to the fluorescent
nanoparticles (data not shown). Some details of the physicochem-
ical characterization (average diameters, polydispersity indices and
zeta potentials) of the blank nanoparticles, quercetin-loaded
nanoparticles, and b-coumarin-loaded nanoparticles that were
used in this research are also reported (Table 1).
Figure 3. Protection exerted by quercetin-loaded nanoparticles on CD36 and b1-integrin, IL-8, MCP-1, and MMP-9 expression
induced by oxysterols. Gene expression was quantified by real-time RT-PCR in SH-SY5Y cells treated for 6 h with 5 mM 7b-hydroxycholesterol (7b-
OH), 24-hydroxycholesterol (24-OH), 27-hydroxycholesterol (27-OH). Some cells were pretreated for 1 h with 5 mM free quercetin (QF) or with 5 mM
quercetin loaded into nanoparticles (QN) before oxysterol treatment. Untreated cells (Control) were taken as controls, and cells treated with 31.2 mM
ethanol (Et-OH) as solvent controls. Cells supplemented with blank nanoparticles (NPs) or with blank nanoparticles plus oxysterols, were taken as
internal controls. Data, normalized to b2-microglobulin, are expressed as mean values 6 SD of five different experiments. *P,0.05, **P,0.01, and
***P,0.001 vs. control; #P,0.05, ##P,0.01, and ###P,0.001 vs. the specific oxysterol; 1P,0.05, 11P,0.01, and 111P,0.001 vs. QF+ specific
oxysterol.
doi:10.1371/journal.pone.0096795.g003
Figure 4. Protection exerted by quercetin-loaded nanoparticles on CD36 and b1-integrin, IL-8, and MCP-1 expression induced by
the oxysterol mixture. Gene expression was quantified by real-time RT-PCR in SH-SY5Y cells treated for 6 h with 15 mM oxysterol mixture (Mix).
Some cells were pretreated for 1 h with 5 mM free quercetin (QF) or with 5 mM quercetin loaded into nanoparticles (QN) before oxysterol treatment.
Untreated cells (Control) were taken as controls, and cells treated with 93.6 mM ethanol (Et-OH) as solvent controls. Cells supplemented with blank
nanoparticles (NPs) or with blank nanoparticles plus oxysterol mixture were taken as internal controls. Data, normalized to b2-microglobulin, are
expressed as mean values 6 SD of five different experiments. *P,0.05, **P,0.01, and ***P,0.001 vs. control; #P,0.05, ##P,0.01, and ###P,
0.001 vs. the specific oxysterol; 11P,0.01 vs. QF+ specific oxysterol.
doi:10.1371/journal.pone.0096795.g004
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The cells were therefore then preincubated with QF or QN for
1 h and then with the oxysterols for 6 h. As already reported in
Figure 1, expression of the inflammatory mediators up-regulated
by oxysterols was investigated by real time RT-PCR. In SH-SY5Y
cells, a marked and statistically-significant increase of the
expression of the molecules considered was evident after incuba-
tion with any of the three oxysterols or with the oxysterol mixture
compared with controls (Figure 3 and 4). Cell pretreatment with
QF did not appreciably prevent expression increase of these
inflammatory molecules induced by the three oxysterols (Figure 3).
Of great interest, conversely, cell pretreatment with QN produced
a clear and statistically-significant down-regulation of these
molecules (Figure 3). A similar set of data was obtained when
cells were pretreated with QN and then incubated for 6 h with the
oxysterol mixture compared with QF pretreated cells (Figure 4).
MMP-9 gene was not taken into consideration because its
expression was not significantly up-regulated by the oxysterol
mixture (see Figure 1). In all experiments, cells treated with
ethanol (Et-OH) or with blank nanoparticles (NPs) remained
unaffected (Figure 3 and 4). Moreover, cell pretreatment with NPs
did not interfere with the oxysterols, showing that NPs did not
affect the induction of the inflammatory molecule expression
induced by the oxysterols themselves (Figure 3 and 4).
Effects of oxysterols on TLR4 and prevention of its up-
regulation by QN cell pretreatment
Up-regulation of TLR4 can contribute to neuroinflammation
by amplifying pro-inflammatory cytokine and chemokine release
[8,56]. To determine whether oxysterols might increase TLR4
expression, SH-SY5Y cells were incubated with each individual
oxysterol (5 mM) or with a mixture (15 mM) of the three for 3 h.
Expression of TLR4 was greatly stimulated, but cell pretreatment
(1 h) with 5 mM QN significantly improved down-regulation of
TLR4, in particular in cells treated with 24-OH or 27-OH,
compared with cell pretreatment (1 h) with 5 mM QF (Figure 5),
pointing to the efficacy of this drug delivery system.
Effects of oxysterols on COX-2 and mPGES-1: down-
regulation by QN cell pretreatment
Since COXs are up-regulated in many inflammatory disorders
including AD [57], to investigate whether oxysterols might be
capable of synthesizing the isoform COX-2 in response to
inflammatory mediators release, cells were incubated with the
oxysterols for 48 h. At the end of the experiment, a significant
increase of COX-2 protein levels was observed in SH-SY5Y cells
incubated with the individual oxysterols (5 mM) and in those
treated with the oxysterol mixture (15 mM) (Figure 6A). Again, 24-
OH and 27-OH appear to be the oxysterols contributing most to
neuroinflammation.
Besides COX-2, also mPGES-1 is up-regulated during the
neuroinflammatory response, with subsequent production of
PGE2, which has inflammatory action that impairs brain function.
A significant increase of mPGES-1 expression has been observed
in cells incubated for 6 h with any of the three oxysterols
(Figure 6B). Cell pretreatment with 5 mM QF significantly reduced
the expression of mPGES-1 but cell pretreatment with 5 mM QN
showed a greater reduction of the enzyme expression (Figure 6B).
Discussion
Neuroinflammation, whether as cause or consequence of AD,
plays a central role in the pathogenesis of this neurodegenerative
disease [4–8]. The importance of neuroinflammatory processes
has been emphasized during the past decade, as intensive
investigations have examined pro-inflammatory mediators and
free radical-mediated oxidative stress, both of which potentially
contribute to further neuronal dysfunction and cell death, as well
as to glial cell activation in the brain of AD patients [14–18].
Although neuroinflammation principally involves activating the
microglia and astrocytes, it has recently been suggested that
neurons themselves may react and contribute to the chronic
neuroinflammatory changes in AD, by serving as a source of
inflammatory mediators [6].
Of note, epidemiological and biochemical data also seem to
suggest that there may be a mechanistic link among altered brain
cholesterol metabolism, neuroinflammation and AD pathogenesis
[22,23,26–28]. The idea that oxysterols, a class of cholesterol
oxidation products, might be the missing link between altered
brain cholesterol metabolism and AD has gained increasing
support as a growing body of evidence suggests the involvement of
24-OH and 27-OH in neurotoxicity [23]. In our recent studies, we
found that the three oxysterols 24-OH, 27-OH and 7b-OH, and
4-hydroxynonenal (HNE) (the most reactive end-product of lipid
peroxidation, which contributes to neuron dysfunction and death),
strongly enhance the binding and accumulation of Ab1-42 on
membranes of human differentiated neuronal cell lines (SK-N-BE
and NT-2) and of human dental-pulp neuron-like cells (DPNLC),
respectively. The mechanism involves the marked increase of the
availability of the multireceptor complex CD36/b1-integrin/
CD47. Interesting findings of these studies are that only 24-OH
and HNE significantly potentiate the neurotoxic action of Ab1–42
on these cells by locally increasing ROS steady-state levels [58,59].
Moreover, in neuronal SK-N-BE and NT-2 cells, 24-OH and 27-
OH have been shown to enhance expression and activity of the b-
Figure 5. Protective effect of quercetin-loaded nanoparticles
on TLR-4 expression induced by oxysterols. Gene expression was
quantified by real-time RT-PCR in SH-SY5Y cells treated for 3 h with
5 mM 7b-hydroxycholesterol (7b-OH), 24-hydroxycholesterol (24-OH),
27-hydroxycholesterol (27-OH), or 15 mM oxysterol mixture (Mix). Some
cells were pretreated for 1 h with 5 mM free quercetin (QF) or with 5 mM
quercetin loaded into nanoparticles (QN) before oxysterol treatment.
Untreated cells (Control) were taken as controls. Data, normalized to b2-
microglobulin, are expressed as mean values 6 SD of three different
experiments. ***P,0.001 vs. control; ##P,0.01 and ###P,0.001 vs.
specific oxysterol; 111P,0.001 vs. QF+ specific oxysterol.
doi:10.1371/journal.pone.0096795.g005
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Figure 6. Effect of oxysterols on COX-2 synthesis and mPGES-1 expression. (A) SH-SY5Y cells were treated for 48 h with 5 mM 7b-
hydroxycholesterol (7b-OH), 24-hydroxycholesterol (24-OH), 27-hydroxycholesterol (27-OH) or 15 mM oxysterol mixture (Mix). Untreated cells (Control)
were taken as controls. COX-2 levels were analyzed by Western blotting. Top: blot representative of three experiments. Bottom: histogram
representing mean values 6 SD of three experiments. COX-2 densitometric measurements were normalized against the corresponding actin levels
and expressed as percentages of control value.**P,0.01 and ***P,0.001 vs. control. (B) mPGES-1 expression was quantified by real-time RT-PCR in
SH-SY5Y cells treated for 6 h with 5 mM 7b-OH, 24-OH, 27-OH or 15 mM oxysterol mixture. Some cells were pretreated for 1 h with 5 mM free
quercetin (QF) or with 5 mM quercetin loaded into nanoparticles (QN) before oxysterol treatment. Untreated cells (Control) were taken as controls.
Data, normalized to b2-microglobulin, are expressed as mean values 6 SD of three different experiments. ***P,0.001 vs. control; ###P,0.001 vs.
specific oxysterol.
doi:10.1371/journal.pone.0096795.g006
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and c-secretases of the amyloidogenic pathway of amyloid
precursor protein processing, leading to increased Ab synthesis
and accumulation in those cells [60]. Further, as regards the
potential neurotoxicity of oxysterols, 24-OH has also been shown
to cause cell death when added to undifferentiated (50 mM) and
differentiated (25–50 mM) SH-SY5Y cells, an affect that was
mediated by increased generation of free radicals [61,62]. The
neurotoxicity of 24-OH was partially prevented by the free radical
scavenger vitamin E (a-tocopherol) and by estradiol-17b [62].
Moreover, 7b-OH has been found to be neurotoxic at nanomolar
concentrations in cultured rat hippocampal neuronal cells, and
may therefore contribute to Ab-related neurodegeneration in the
brain of AD patients [25]. Another oxysterol that has been found
responsible for necrotic cell death of SH-SY5Y cells is 7a-
hydroperoxycholesterol, which might derive from the auto-
oxidation of cellular cholesterol, released during neurodegenera-
tion [63]; a further possibility is 7-ketocholesterol [64]. Addition-
ally, in agreement with Gamba and colleagues [60] 24-OH has
been shown to enhance the neurotoxic effect of the Ab1–42 peptide
in the human differentiated neuroblastoma cell line MSN, as well
as augmenting ROS generation [65]. There is also mounting
evidence that treatment with oxysterols enhances the release of a
number of inflammatory molecules in a wide variety of cell types
[45–50].
Although oxysterols have been studied for their involvement in
oxidative stress and inflammatory processes, and in the subse-
quent cell death during AD progression [23], it is now emerging
that they play a role as ligands (e.g. 24-OH and 27-OH) for liver
X receptors (LXRs), transcription factors that regulate an array of
genes, among them the genes involved in cholesterol efflux and
metabolism [66,67]. Indeed, astrocytes are sensitive to 24-OH-
mediated up-regulation of the LXR-responsive genes involved in
cholesterol efflux: ATP-binding cassette transporter A1 and G1
(ABCA1 and ABCG1) and apolipoprotein E [68]. Of note,
contrary to Gamba and colleagues [60], 27-OH, as an LXR
ligand, has been shown to significantly exert anti-amyloidogenic
effects, by reducing Ab peptide generation from primary human
neurons, in turn by up-regulating LXR responsive genes [69].
Recent in vitro evidence also suggests that LXR activation by 24-
OH and 27-OH may contribute to decreasing the Ab peptide
influx across the BBB, with involvement of the ABCB1
transporter, leading to protection from peripheral Ab entry
[70]. Conversely, treatment of brain pericytes with 24-OH
caused an increase in ABCA1 expression correlated with an
increase of cholesterol efflux, but 24-OH treatment was found not
to reduce the ability of the pericytes to accumulate Ab in the cells
[71]. The clearance of Ab also seems to be mediated through
microglia-induced phagocytosis, which is dependent on LXR
activation [72].
Of note, LXR activation not only affects gene regulation of
cholesterol homeostasis, and Ab peptide transport and clearance,
but also inflammation in the brain. Studies have demonstrated
that LXR activation inhibits AD-related inflammatory responses
and inflammatory gene expression, owing to LXR’s ability to
functionally inactivate the promoters of pro-inflammatory
genes and of nuclear factor-kB (NF-kB) [73–78]. Moreover,
LXR activation may prevent an inflammatory response by
indirectly supporting repression of TLR target gene activation,
which may modulate inflammatory signaling via several
routes.
However, although LXR-activating oxysterols might reduce
membrane cholesterol content and inflammation, they can also act
by activating opposing pathways and inducing expression of
inflammation markers independently of LXRs in endothelial cells
[46].
In this study we report clear evidence that the oxysterols
potentially involved in AD pathogenesis markedly enhance pro-
inflammatory mediator expression, which plays a critical role in
mediating AD-associated changes, also by driving a self-sustain-
ing cycle that exacerbates neuron loss. In this connection, we
found that 24-OH and 27-OH, but also 7b-OH, induced
expression of IL-8, MCP-1, b1-integrin, CD36, and MMP-9 in
human neuroblastoma SH-SY5Y cells. The chemokines IL-8 and
MCP-1 are important mediators for both microglia and astrocyte
recruitment and activation as well as leukocyte infiltration around
the areas of neuroinflammation [79,80]. The adhesion molecule
b1-integrin also plays a critical role in regulating leukocyte
migration through ECM to the site of inflammation, by
mediating cell-cell interactions and by connecting the ECM
molecules to the cellular cytoskeleton [81]. Moreover, MMP-9
has been identified in neuroinflammation and, of note, its
expression is regulated, among other factors, by cytokines
[82,83]. In addition, the scavenger receptor CD36 plays a
fundamental role in binding the Ab peptide [58] as well as in
cerebrovascular oxidative stress and neurovascular dysfunction
induced by Ab, promoting inflammation [84]. Of note, some of
the pro-inflammatory effects of CD36 have been attributed to its
association with TLRs heterodimers (TLR2/1, TLR2/6, or
TLR4/6) as co-receptor, leading to NF-kB activation and pro-
inflammatory gene expression. In particular, the pro-inflamma-
tory signaling of Ab depends on its interaction with CD36 which
induce the downstream signaling cascades required for TLR4/6
activation [85]. It is thus clear that TLR4 activation contributes
to neuroinflammation by amplifying the release of pro-inflam-
matory mediators [8,51].
On this basis, we here show that oxysterols can stimulate
TLR4 expression, potentially leading to an increase of inflam-
matory molecule release in SH-SY5Y cells. Other research
groups have reported the hypothesis that oxysterols might
promote inflammation via TLR2/4 activation [86,87]. More-
over, we found that oxysterols increase the levels of COX-2, as
well as expression of mPGES-1, both of which are stimulated by
cytokine and chemokine release, with subsequent production of
prostaglandin E2. These molecular mechanisms, induced by
oxysterols, thus play a fundamental role in the neuroinflamma-
tory changes in AD.
To highlight the inflammatory actions of these oxysterols, we
preincubated the cells with the bioflavonoid quercetin, which, as
do the other polyphenols, exerts neuroprotective action. The
polyphenols attenuate or prevent oxidative stress and inflamma-
tory changes, thanks to their anti-oxidant, anti-inflammatory, and
anti-amyloidogenic activities [30–35]. Because quercetin, like the
other polyphenols, cannot easily pass through the BBB, and like
most of them has limited bioavailability and is extensively
metabolized [39,40], to investigate a new delivery form that
would improve its bioavailability, and consequently its anti-
inflammatory activity, quercetin was delivered to cells loaded into
b-CD-dodecylcarbonate nanoparticles. The anti-inflammatory
effect of quercetin-loaded nanoparticles was markedly stronger
than that of free quercetin. The ability of quercetin-
loaded nanoparticles to prevent or reduce inflammatory
molecule expression is also been demonstrated by the fact that
it can down-regulate the TLR4 and COX-2 signaling
cascades.
Although further studies are required to elucidate the precise
mechanisms and action of quercetin-loaded nanoparticles, the
present findings support the hypothesis that this drug delivery
Quercetin-Loaded Nanoparticle in Neuroinflammation
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system might be a potential new therapeutic tool, that could
increase quercetin’s neuroprotective effects by improving its
permeation across the BBB into the brain, and its bioavailability,
thus its ability to reach target cells.
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